While our study demonstrates that PD-1CAR Tregs can simultaneously engage, activate, and suppress pathogenic PD-1+ immune cells in vitro, in vivo validation in autoimmune disease models—such as EAE for MS—is necessary to fully assess the safety, efficacy, biodistribution, and stability of these engineered cells. This evidence concerns the gene PDCD1 and myeloid sarcoma.